From the secondary analysis, the significantly less conservative but clinically meaningful criterion of steady reaction (outlined for a fifty% or more reduction in MADRS from baseline for 2 weeks) was used. On the patients who realized secure response, 25.eight% inside the esketamine group and fifty seven.6% inside the placebo group https://margaretx146nkj9.tnpwiki.com/user